The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

NCT07073053 on ClinicalTrials.gov · last registry update 2025-07-18

Registered but not yet open, with 60 participants planned. Due to report 31 July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: change of Time-in-range (%). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor type: Other Gov
Enrollment: 60
Started: 2025-10-01
Primary completion: 2028-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

change of Time-in-range (%)

Conditions studied

Glucagon-Like Peptide-1 Receptor Agonists · Type 2 Diabetes · Coronary Arterial Disease (CAD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.